🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525898-39-00
Authorised Phase III

The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI

2026-525898-39-00 · tracked via the Priya Life Science EU tracker
Sponsor
Azienda Sanitaria Locale Napoli 1 Centro
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Neoplasms
Decision date
14/08/2026
Enrollment target
1700
Sites
Italy

Condition studied

Advanced hepatocellular carcinoma

Investigational medicinal product(s)

CABOZANTINIBCABOZANTINIBCABOZANTINIBATEZOLIZUMABDURVALUMABBEVACIZUMABREGORAFENIBLENVATINIBTREMELIMUMABSORAFENIB

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

OS (Overall Survival)

Endpoint detail

Progression-free survival (PFS), overall response rate (ORR), quality of life (QoL), and safety/tolerability, financial toxicity, prognostic and predictive value of geriatric assessment parameters in the elderly population assessed through ADL, IADL, and G8 questionnaires, healthcare resource utilization, treatment costs, cost-effectiveness and cost-utility

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525898-39-00 on CTIS ↗ ← All trials in the EU